EU Regulation on advanced therapies

The regulatory framework for advanced therapy medicinal products (ATMPs) is established by Regulation (EC) No 1394/2007 on advanced therapy medicinal products which is designed to ensure the free movement of these medicines within the European Union (EU), to facilitate their access to the EU market, and to foster the competitiveness of European pharmaceutical companies in the field, while guaranteeing the highest level of health protection for patients.

Implementation of the Regulation

The Committee for Advanced Therapies (CAT) was established in accordance with the Advanced Therapies Regulation as a multidisciplinary committee, whose primary responsibility is to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. Since June 2009 the CAT issues scientific recommendations on ATMPs classification.

Additional EU Regulation

• Commission directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products
• Commission regulation (EC) No 668/2009 of 24 July 2009 implementing Regulation (EC) No 1394/2007 of the European Parliament and of the Council with regard to the evaluation and certification of quality and non-clinical data relating to advanced therapy medicinal products developed by micro, small and medium-sized enterprises
• Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC Regulation (EC) No 726/2004